InvIos获得82万欧元A系列资金,与Dana-Farber合作,并计划在2025年为INV441进行临床研究。 invIOs secures €8.2m Series A funding, collaborates with Dana-Farber, and plans clinical studies for INV441 in 2025.

专门从事癌症治疗的生物技术公司InvIos已获得A系列820万欧元的资金,用于在2025年之前推进研究和临床发展。 invIOs, a biotech firm specializing in cancer therapies, has secured €8.2 million in Series A funding to advance its research and clinical development through 2025. 该公司正与Dana-Farber癌症研究所合作开展两个关键方案:INV441,一种使用经修改的肿瘤过滤淋巴细胞的细胞疗法,和INV501,一种口服小分子,增强T细胞反应。 The company is collaborating with the Dana-Farber Cancer Institute on two key programs: INV441, a cell therapy using modified tumor-infiltrating lymphocytes, and INV501, an oral small molecule enhancing T cell responses. INV441临床研究预计将于2025年年中开始。 Clinical studies for INV441 are expected to begin in mid-2025.